Browse FOS

Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Endoplasmic reticulum. Cytoplasm, cytosol. Note=In quiescent cells, present in very small amounts in the cytosol. Following induction of cell growth, first localizes to the endoplasmic reticulum and only later to the nucleus. Localization at the endoplasmic reticulum requires dephosphorylation at Tyr-10 and Tyr-30.
Domain PF00170 bZIP transcription factor
Function

Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor. In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regulating the development of cells destined to form and maintain the skeleton. It is thought to have an important role in signal transduction, cell proliferation and differentiation. In growing cells, activates phospholipid synthesis, possibly by activating CDS1 and PI4K2A. This activity requires Tyr-dephosphorylation and association with the endoplasmic reticulum.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001661 conditioned taste aversion
GO:0002237 response to molecule of bacterial origin
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006304 DNA modification
GO:0006305 DNA alkylation
GO:0006306 DNA methylation
GO:0006979 response to oxidative stress
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0007565 female pregnancy
GO:0007568 aging
GO:0007611 learning or memory
GO:0007612 learning
GO:0007631 feeding behavior
GO:0008306 associative learning
GO:0009266 response to temperature stimulus
GO:0009314 response to radiation
GO:0009409 response to cold
GO:0009416 response to light stimulus
GO:0009612 response to mechanical stimulus
GO:0009629 response to gravity
GO:0009636 response to toxic substance
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0014074 response to purine-containing compound
GO:0014706 striated muscle tissue development
GO:0030099 myeloid cell differentiation
GO:0030316 osteoclast differentiation
GO:0030431 sleep
GO:0031668 cellular response to extracellular stimulus
GO:0031960 response to corticosteroid
GO:0032259 methylation
GO:0032496 response to lipopolysaccharide
GO:0032570 response to progesterone
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0035902 response to immobilization stress
GO:0035914 skeletal muscle cell differentiation
GO:0035994 response to muscle stretch
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042493 response to drug
GO:0043414 macromolecule methylation
GO:0044706 multi-multicellular organism process
GO:0044708 single-organism behavior
GO:0044728 DNA methylation or demethylation
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045672 positive regulation of osteoclast differentiation
GO:0046683 response to organophosphorus
GO:0048545 response to steroid hormone
GO:0050890 cognition
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051384 response to glucocorticoid
GO:0051385 response to mineralocorticoid
GO:0051412 response to corticosterone
GO:0051591 response to cAMP
GO:0051592 response to calcium ion
GO:0060395 SMAD protein signal transduction
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071277 cellular response to calcium ion
GO:0071496 cellular response to external stimulus
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:1901654 response to ketone
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1902895 positive regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0008134 transcription factor binding
GO:0046332 SMAD binding
GO:0046982 protein heterodimerization activity
GO:0070412 R-SMAD binding
Cellular Component GO:0005667 transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04024 cAMP signaling pathway
hsa04210 Apoptosis
hsa04380 Osteoclast differentiation
hsa04620 Toll-like receptor signaling pathway
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04668 TNF signaling pathway
hsa04713 Circadian entrainment
hsa04725 Cholinergic synapse
hsa04728 Dopaminergic synapse
hsa04915 Estrogen signaling pathway
hsa04917 Prolactin signaling pathway
hsa04921 Oxytocin signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-450341: Activation of the AP-1 family of transcription factors
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-450282: MAPK targets/ Nuclear events mediated by MAP kinases
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-449147: Signaling by Interleukins
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FOS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FOS and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23319273Prostate CarcinomaInhibit immunityStudies revealed that the levels of expression of genes responsible for T-cell proliferation (C-FOS, C-JUN and DUSP1) and cellular migration (RGS1) were greater in Tregs from mCRPC patients as compared to values observed in healthy donors.
Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FOS in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FOS in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0920.862
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1020.972
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2480.898
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.7430.414
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4590.883
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0930.794
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2240.656
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1750.917
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1870.914
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3310.399
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.0450.155
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3730.0928
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FOS in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 1417011.8-11.80.488
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOS.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FOS expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FOS and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFOS
NameFBJ murine osteosarcoma viral oncogene homolog
Aliases c-fos; v-fos FBJ murine osteosarcoma viral oncogene homolog; FBJ murine osteosarcoma viral (v-fos) oncogene ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FOS collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FOS.
ID Name Drug Type Targets #Targets
DB00852PseudoephedrineSmall MoleculeADRA1A, ADRA2A, ADRB1, ADRB2, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6, ......20
DB08813NadroparinSmall MoleculeFOS, MYC, SELP, SERPINC14